Sight Sciences NASDAQ:SGHT President and CEO Paul Badawi sold 29,244 shares of common stock on April 1, 2026, according to a Securities and Exchange Commission filing. The shares were disposed of at prices between $3.63 and $3.85 per share, producing total proceeds of $108,202.
The SEC filing indicates the sale was undertaken to satisfy the tax liability tied to the vesting of restricted stock units. After the transaction, Badawi's direct ownership in Sight Sciences stands at 6,151,156 shares. That total comprises 5,544,983 shares of Common Stock plus 606,173 shares of Common Stock that will be acquired upon vesting and settlement of RSUs that have not yet vested.
At the time of the filing, the company's shares were trading at $3.52, a price level that represents a 9.3% decline over the prior week. Analysis from InvestingPro cited in the filing suggests Sight Sciences remains slightly undervalued at current levels.
Separately, the company recently released fourth quarter 2025 financial results that exceeded analysts' expectations. Sight Sciences reported earnings per share of negative $0.08, ahead of the anticipated negative $0.15. Quarterly revenue reached $20.4 million, topping the forecast of $20.17 million and reflecting a 7% increase from previously reported figures.
In legal developments disclosed alongside the financial update, a U.S. District Court awarded Sight Sciences $34 million in damages related to patent infringement by Alcon Inc. The $34 million award comprises $5.5 million classified as lost profits and $28.5 million in royalty damages.
Investment research house William Blair reiterated an Outperform rating on Sight Sciences following the results, citing effective expense control as a notable factor in the company's recent performance. The quarterly report was consistent with a preannouncement the company issued in January.
Taken together, the insider sale to cover RSU-related taxes, the modest beat on revenue and EPS in Q4 2025, and the court-ordered damages award are the principal items disclosed in the filings and reports. The documentation does not provide additional commentary on future management stock activity or on how the company plans to allocate litigation proceeds.
Summary of key facts
- Paul Badawi sold 29,244 shares on April 1, 2026, at $3.63 to $3.85 per share for $108,202 total.
- Post-sale, Badawi directly owns 6,151,156 shares, including 606,173 RSUs that have not vested.
- Q4 2025 EPS was -$0.08 versus an expected -$0.15; revenue was $20.4 million versus a $20.17 million forecast, up 7% from prior figures.
- A U.S. District Court awarded Sight Sciences $34 million in patent damages from Alcon Inc., split into $5.5 million in lost profits and $28.5 million in royalty damages.